PREDICT
PREDICT: A Prospective, Multicenter Real-World Study to Describe the Clinical Outcome and Quality of Life in Chinese Post-operative CRSwNP Patients
Sponsor study identifier
observational
146
1 country
21
Study Start
March 19, 2026
Actual (reported)Primary Completion
October 21, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
October 21, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
This is a prospective, multicenter real-world observational study designed to describe post-operative outcomes, quality of life, disease control, recurrence-related characteristics, economic burden and post-operative treatment patterns in Chinese patients with CRSwNP undergoing endoscopic sinus surgery (ESS).
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
October 21, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 26, 2026
Actual (reported)March 3, 2026
Actual (reported)March 19, 2026
Actual (reported)October 21, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
October 21, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
The observed value and change from baseline in SNOT-22 total score at week-52
To describe the Sino-Nasal Outcome Test (SNOT)-22 total score at 52 weeks post- operatively. \[SNOT-22: score 0-5 each item, 5 means worse outcome, 22 items totally\]
baseline-week52
The observed value and change from baseline in MLK score at week-52
To describe the Modified Lund-Kennedy (MLK) score at 52 weeks post-operatively. \[MLK score: score 0-24, 24 means worse outcome\]
baseline-week52
The observed values and changes from baseline at each collection point: VAS - Total sinus symptoms item
baseline-week52
The observed values and changes from baseline in NPS at each collection point
baseline-week52
The observed values and changes from baseline at each collection point: VAS - Nasal blockage item
baseline-week52
The observed values and changes from baseline at each collection point: SNOT-22 Smell/taste Item Score
baseline-week52
The observed values and changes from baseline at each collection point: SNOT-22 Nasal Congestion Item Score
baseline-week52
T2：bEOS≥150 cells/μL or Tissue EOS≥10/hpf or Total IgE≥100 IU/ml.
Baseline
bEOS: <150，150-300，≥300 cells/μL.
Baseline
Tissue EOS≥10/hpf.
Baseline
This is a prospective, multicenter real-world observational study .Patients will receive standard medical care as determined by the treating physician according to routine clinical practice at each site. No treatment assignment will be made as part of the study.
Patients will receive standard medical care as determined by the treating physician according to routine clinical practice at each site. No treatment assignment will be made as part of the study.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Chinese CRSwNP Patients
The Seventh Affiliated Hospital Sun Yat-sen University
Guangzhou, Guangdong, 518106, China
Shengjing Hospital of China Medical University
Shenyang, Liaoning, 110002, China
QiLu Hospital of Shandong University
Jinan, Shandong, 250012, China
Research Site
Changchun, 130033, China
Research Site
Changsha, China
Research Site
Chengdu, 610078, China
Research Site
Guangzhou, 510062, China
No Retention of biospecimen.
Weiping Wen, Professor
First Affiliated Hospital, Sun Yat-Sen University
Dongdong Zhu, Professor
China-Japan Union Hospital, Jilin University
146 participants (actual enrollment reported by the registry).
First Submitted
January 26, 2026
First Posted
March 3, 2026
Study Start
March 19, 2026
Actual (reported)Efficacy and Safety of SHR-1905 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps
Contact the study team to confirm eligibility.
Research Site
Guangzhou, 514700, China
Research Site
Guangzhou, China
Research Site
Haikou, 570311, China
Research Site
Kunming, China
Research Site
Nanchang, China
Research Site
Nanjing, China
Research Site
Nanning, 530021, China
Research Site
Qingdao, China
Research Site
Shanghai, 200031, China
Research Site
Shenzhen, China
Research Site
Ürümqi, 830054, China
Research Site
Wuhan, 430000, China
Research Site
Wuhan, China
Research Site
Xiamen, 361003, China
Primary Completion
October 21, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
October 21, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
September 25, 2026
Record last verified: 2026-09
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: